Pirtobrutinib+Pola-R-CHP for Newly Diagnosed Non-GCB DLBCL
NCT07744724
·
clinicaltrials.gov ↗
PHASE2
Phase
NOT_YET_RECRUITING
Status
48
Enrollment
OTHER
Sponsor class
Conditions
DLBCL - Diffuse Large B Cell Lymphoma
Pirtobrutinib
Interventions
DRUG:
Pirtobrutinib+Pola-R-CHP
Sponsor
Changzhou No.2 People's Hospital